Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020

Summary

GlobalData, Industry analysis specialist, has released its new report, "Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020", an essential and comprehensive source of information and analysis on the global Pulmonary Arterial Hypertension (PAH) therapeutics market. The report identifies and analyzes the key trends shaping and driving the global PAH therapeutics market, as well as treatment usage patterns in the global PAH therapeutics market. The competitive landscape is also covered, with insights into the emerging players expected to significantly alter the positions of the existing market leaders. An in-depth analysis of current pipeline products offers up valuable insights, and the report quantifies the unmet need in the global PAH therapeutics market as well as in the markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China, India and Russia, highlighting opportunities for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the global PAH therapeutics market was worth around $3.3 billion in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 38.6% from 2002 to 2011. PAH is a rare indication but despite the small patient volume, the market showed a tremendous growth in the historic period. This growth was due to the significant drug development activity corresponding to the launch of around eight premium priced drugs in the PAH therapeutics market from 2002 to 2011. Patient volume also increased during this period due to the increasing awareness.

The drugs used in the treatment of PAH are Tracleer (bosentan), Letairis (ambrisentan), Remodulin (treprostinil), Ventavis (iloprost), Revatio (sildenafil), Adcirca (tadalafil), Tyvaso (inhaled treprostinil) and Veletri (epoprostenol). The uptake of these drugs drove the market because of increase in Annual Cost of Therapy (ACOT) of PAH.

The global PAH therapeutics market is estimated to be worth $3.1 billion in 2020. It is forecast to show a negative CAGR of 0.6% from 2011 to 2020.

In 2011, the leading drugs in G7 market (the US, France, Germany, Italy, Spain, the UK and Japan) were Tracleer, Revatio, Letairis/Volibris and Remodulin with sales of $1,303.3m, $439.0m, $364.3m and $363.7m respectively.

Scope

The scope of the report includes -

• An overview of PAH which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized global PAH therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2002 to 2011, and forecast to 2020.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, Japan, Brazil, Russia, India and China.
• An insightful review of the key industry drivers, restraints and challenges, and predicted impact of key events
• Competitor assessment including drug launch analysis and drug sales forecasts
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, Life Cycle Management (LCM) activities, product positioning and drug sales forecast.
• Analysis of unmet need in the market and target product profiles, including opportunities for target products
•Technology trends and analytic frameworks to assess pipeline strength
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The major mechanisms are Nitric Oxide (NO)-based vasodilation, prostanoid receptor agonists, tyrosine kinase inhibitors and PDE-5 inhibitors
• Clinical trials mapping of trials for PAH in different regions
• An overview of the most promising drugs, including clinical study details, efficacy, safety, collaboration agreements, marketing rights, launch analysis and drug sales forcasts to 2020
• Analysis of the current and future market competition in the global PAH therapeutics market. Company profiles including business description, financial overview and SWOT analyses of key future market players including Bayer, Novartis, Actelion and United Therapeutics Corporation.
• Analysis of licensing agreements during 2008-2011 in the PAH therapeutics market, and M&A analysis including M&A deals
• Strategic assessment of the market through market impact analyses, future market scenarios and company analyses.
• Direct quotes from Key Opinion Leaders and physicians in the PAH therapeutics market.

Reasons to buy

This report will enhance your decision-making capability by enabling you to -

• Develop business strategies and perform superior market quantification analysis by
• Understanding the trends shaping and driving the global PAH therapeutics market.
• Understanding treatment preferences of physicians in disease stages and across treatment flow.
• Accessing market sizing, forecasts and quantified growth opportunities in the global PAH therapeutics market through to 2020.
• Quantifying patient population in the global PAH therapeutics market to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
• Performing benchmarking analysis and growth opportunities against currently marketed products
• Identifying market entry points based on safety, efficacy, and pricing parameters
• Assessing competitiveness of products in market by understanding the strengths and weaknesses of current competition
• Develop and design your in-licensing and out-licensing strategies by
• Taking a comprehensive look of at the disease pipeline and identifying the most promising products.
• Assessing the strength of the pipeline based on the presence of first-in-class, me-too and generic drugs and where they are in their development cycles
• Track drug sales in the global PAH therapeutics market from 2002 to 2020.
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• Identify what the next big thing in the market is going to be to capitalize on it.

1.1 List of Tables 7
1.2 List of Figures 11
2 Pulmonary Arterial Hypertension - Disease Overview 17
2.1 Overview 17
2.2 Clinical Classification of Pulmonary Hypertension 17
2.3 Epidemiology of Pulmonary Hypertension 20
2.4 Pathophysiology 21
2.5 Symptoms 23
2.6 Diagnosis 23
2.6.1 Diagnostic Techniques 25
2.6.2 Evaluation of Disease Severity 27
2.7 Treatment 27
2.8 GlobalData Pipeline Report Guidance 31
3 Pulmonary Arterial Hypertension Therapeutics - Market Characterization 32
3.1 Global 32
3.1.1 Market Size 32
3.1.2 Drivers & Barriers 40
3.1.3 Impact on the market 41
3.1.4 Forecasts 42
3.1.5 Future Impact 49
3.1.6 Drug Sales 50
3.2 The US 52
3.2.1 Market Size 52
3.2.2 Drivers and Barriers 56
3.2.3 Impact on the market 58
3.2.4 Forecasts 59
3.2.5 Future Impact 63
3.2.6 Drug Sales 64
3.2.7 Pricing and Reimbursements 66
3.3 The UK 67
3.3.1 Market Size 67
3.3.2 Drivers and Barriers 71
3.3.3 Impact on the Market 73
3.3.4 Forecasts 74
3.3.5 Future Impact 78
3.3.6 Drug Sales 79
3.3.7 Pricing and Reimbursements 81
3.4 Germany 82
3.4.1 Market Size 82
3.4.2 Drivers and Barriers 86
3.4.3 Impact on the Market 88
3.4.4 Forecasts 89
3.4.5 Future Impact 93
3.4.6 Drug Sales 94
3.4.7 Pricing and Reimbursements 96
3.4.8 Market Size 97
3.4.9 Drivers and Barriers 101
3.4.10 Impact on the Market 103
3.4.11 Forecasts 104
3.4.12 Future Impact 108
3.4.13 Drug Sales 109
3.4.14 Pricing and Reimbursements 111
3.5 Italy 112
3.5.1 Market Size 112
3.5.2 Drivers and Barriers 116
3.5.3 Impact on the Market 118
3.5.4 Forecasts 119
3.5.5 Future Impact 123
3.5.6 Drug Sales 124
3.5.7 Pricing and Reimbursements 125
3.6 Spain 127
3.6.1 Market Size 127
3.6.2 Drivers and Barriers 131
3.6.3 Impact on the Market 132
3.6.4 Forecasts 133
3.6.5 Future Impact 137
3.6.6 Drug Sales 138
3.6.7 Pricing and Reimbursements 140
3.7 Japan 141
3.7.1 Market Size 141
3.7.2 Drivers and Barriers 145
3.7.3 Impact on the Market 146
3.7.4 Forecasts 147
3.7.5 Future Impact 151
3.7.6 Drug Sales 152
3.7.7 Pricing and Reimbursements 153
3.8 Brazil 154
3.8.1 Market Size 154
3.8.2 Drivers and Barriers 158
3.8.3 Impact on the Market 159
3.8.4 Forecasts 160
3.8.5 Future Impact 164
3.9 Russia 165
3.9.1 Market Size 165
3.9.2 Drivers and Barriers 169
3.9.3 Impact on the Market 170
3.9.4 Forecasts 171
3.9.5 Future Impact 175
3.10 India 176
3.10.1 Market Size 176
3.10.2 Drivers and Barriers 180
3.10.3 Impact on the Market 181
3.10.4 Forecasts 182
3.10.5 Future Impact 186
3.11 China 187
3.11.1 Market Size 187
3.11.2 Drivers and Barriers 191
3.11.3 Impact on the Market 192
3.11.4 Forecasts 193
3.11.5 Future Impact 197
3.12 Key Takeaway 197
4 Pulmonary Arterial Hypertension Therapeutics - Opportunity and Unmet Need 198
4.1 Opportunity for a new product 199
4.2 Key Takeaway 199
5 Pulmonary Arterial Hypertension Therapeutics - Competitive Assessment 200
5.1 Overview 200
5.2 Strategic Competitor Assessment 200
5.3 Product Profile for the Major Marketed Products in the Pulmonary Arterial Hypertension Therapeutics Market 202
5.3.1 Tracleer (bosentan) 202
5.3.2 Letairis/Volibris (ambrisentan) 205
5.3.3 Adcirca (tadalafil) 208
5.3.4 Revatio (sildenafil) 211
5.3.5 Remodulin (treprostinil) 214
5.3.6 Tyvaso (treprostinil) 217
5.3.7 Ventavis (iloprost) 219
5.4 Key Takeaway 221
6 Pulmonary Arterial Hypertension Therapeutics - Pipeline Assessment 224
6.1 Overview 224
6.2 Pipeline Analysis by Phase of Development 224
6.3 Pipeline by Mechanism of Action 225
6.4 Strategic Pipeline Assessment 225
6.4.1 Technology Trends Analytic Framework 225
6.5 Pulmonary Arterial Hypertension Therapeutics Pipeline - By Clinical Phases of Development 227
6.5.1 Pulmonary Arterial Hypertension - Pre-registration 227
6.5.2 Pulmonary Arterial Hypertension - Phase III Clinical Pipeline 228
6.5.3 Pulmonary Arterial Hypertension - Phase II Clinical Pipeline 228
6.5.4 Pulmonary Arterial Hypertension - Phase I Clinical Pipeline 228
6.5.5 Pulmonary Arterial Hypertension - Pre-clinical Pipeline 229
6.6 Pulmonary Arterial Hypertension - Drugs under Clinical Development 229
6.6.1 Oral Treprostinil 229
6.6.2 Imatinib 230
6.6.3 Riociguat 231
6.6.4 Selexipag 231
6.6.5 Macitentan 232
6.6.6 MD-0701 232
6.6.7 Beraprost Sodium-MR 232
6.7 Pulmonary Arterial Hypertension- Partners in Research and Development 234
6.7.1 Licensing Agreements 234
6.7.2 Co-development Agreements 234
6.8 Key Takeaway 235
7 Pulmonary Arterial Hypertension Therapeutics - Clinical Trials Mapping 236
7.1 Clinical Trials 236
7.1.1 Clinical Trials by Status 237
7.1.2 Clinical Trials by Country 238
7.1.3 Clinical Trials by Phase 239
7.1.4 Clinical Trials by Sponsor Type 240
7.1.5 Clinical Trials - Leading Sponsors 241
7.1.6 Clinical Trials - Leading Company Sponsors by Phase 242
7.2 Patient Recruitment 243
8 Pulmonary Arterial Hypertension Therapeutics - Strategic Assessment 244
8.1 Key Events Impacting the Future Market 244
8.2 Future Market Scenario 245
9 Pulmonary Arterial Hypertension Therapeutics - Future Market Players 246
9.1 Introduction 246
9.2 Actelion 246
9.2.1 Business Description 246
9.2.2 Financial Overview 247
9.2.3 SWOT Analysis 248
9.2.4 Pipeline Portfolio 250
9.3 United Therapeutics Corporation 251
9.3.1 Business Description 251
9.3.2 Financial Overview 251
9.3.3 SWOT Analysis 252
9.3.4 Pipeline Portfolio 256
9.4 Novartis AG 256
9.4.1 Business Description 256
9.4.2 Financial Overview 257
9.4.3 SWOT Analysis 257
9.4.4 Pipeline Portfolio 262
9.5 Bayer AG 262
9.5.1 Business Description 262
9.5.2 Financial Overview 263
9.5.3 SWOT Analysis 264
9.5.4 Pipeline Portfolio 267
10 Pulmonary Arterial Hypertension Therapeutics - Mergers and Acquisitions Analysis 268
10.1 Key Deals Analysis 268
10.1.1 Forest Laboratories Completes Acquisition of Clinical Data Inc. 268
10.1.2 Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company 268
10.1.3 Immune Control Merges with Arginetix 268
10.1.4 Pfizer Acquires Terguride from ErgoNex Pharma 268
10.1.5 Actelion Acquires Rights of Epoprostenol from GeneraMedix 269
11 Pulmonary Arterial Hypertension Therapeutics - Expert Opinion 270
11.1 Expert Opinion 270
11.1.1 Treatment Options 270
11.1.2 Future Drugs of PAH Treatment 270
11.1.3 Future Growth Rate of PAH Therapeutics Market 270
11.1.4 Current Unmet Needs in the PAH Treatment 270
11.1.5 What Ideal Features Required in a New Drug 271
11.1.6 Past Patient Trends in PAH 271
12 Appendix 272
12.1 Definitions 272
12.2 Acronyms 272
12.3 Research Methodology 274
12.3.1 Coverage 274
12.3.2 Secondary Research 274
12.3.3 Forecasting 275
12.3.4 Primary Research 278
12.3.5 Expert Panel Validation 278
12.4 Contact Us 278
12.5 Disclaimer 278
12.6 Bibliography 279

List of Tables

1.1 List of Tables
Table 1: Hemodynamic Definitions of Pulmonary Hypertension, 2011 17
Table 2: Clinical Classification of Pulmonary Hypertension (Dana Point, 2008) 18
Table 3: Functional Classification of Pulmonary Hypertension, World Health Organisation 1998 19
Table 4: Parameters with Established Importance for Assessing Disease Severity, Stability and Prognosis in PAH 27
Table 5: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m), 2002-2011 32
Table 6: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2011 34
Table 7: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011 36
Table 8: Pulmonary Arterial Hypertension Therapeutics Market, Global, Patient Volume, 2002-2011 37
Table 9: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, 2002-2011 38
Table 10: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m), 2011-2020 42
Table 11: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m) by Country, 2011-2020 44
Table 12: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020 46
Table 13: Pulmonary Arterial Hypertension Therapeutics Market, Global, Patient Volume, 2011-2020 47
Table 14: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 48
Table 15: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Drug Sales ($m), 2002-2011 50
Table 16: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Drug Sales ($m), 2011-2020 51
Table 17: Pulmonary Arterial Hypertension Therapeutics Market, the US, Sales Value ($m), 2002-2011 52
Table 18: Pulmonary Arterial Hypertension Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2011 53
Table 19: Pulmonary Arterial Hypertension Therapeutics Market, the US, Patient Volume (absolute), 2002-2011 54
Table 20: Pulmonary Arterial Hypertension Therapeutics Market, the US, Treatment Usage Patterns, 2002-2011 55
Table 21: Pulmonary Arterial Hypertension Therapeutics Market, the US, Sales Value ($m), 2011-2020 59
Table 22: Pulmonary Arterial Hypertension Therapeutics Market, the US, Annual Cost of Therapy ($), 2011-2020 60
Table 23: Pulmonary Arterial Hypertension Therapeutics Market, the US, Patient Volume (absolute), 2011-2020 61
Table 24: Pulmonary Arterial Hypertension Market, the US, Treatment Usage Patterns, 2011-2020 62
Table 25: Pulmonary Arterial Hypertension Therapeutics Market, the US, Drug Sales ($m), 2002-2011 64
Table 26: Pulmonary Arterial Hypertension Therapeutics Market, the US, Drug Sales ($m), 2011-2020 65
Table 27: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Sales Value ($m), 2002-2011 67
Table 28: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2011 68
Table 29: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Patient Volume (absolute), 2002-2011 69
Table 30: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Treatment Usage Patterns, 2002-2011 70
Table 31: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Sales Value ($m), 2011-2020 74
Table 32: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011-2020 75
Table 33: Pulmonary Arterial Hypertension Market, the UK, Patient Volume (absolute), 2011-2020 76
Table 34: Pulmonary Arterial Hypertension Market, the UK, Treatment Usage Patterns, 2011-2020 77
Table 35: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Drug Sales ($m), 2002-2011 79
Table 36: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Drug Sales ($m), 2011-2020 80
Table 37: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Sales Value ($m), 2002-2011 82
Table 38: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011 83
Table 39: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Patient Volume (absolute), 2002-2011 84
Table 40: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Treatment Usage Patterns, 2002-2011 85
Table 41: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Sales Value ($m), 2011-2020 89
Table 42: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 90
Table 43: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Patient Volume (absolute), 2011-2020 91
Table 44: Pulmonary Arterial Hypertension Market, Germany, Treatment Usage Patterns, 2011-2020 92
Table 45: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Drug Sales ($m), 2002-2011 94
Table 46: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Drug Sales ($m), 2011-2020 95
Table 47: Pulmonary Arterial Hypertension Therapeutics Market, France, Sales Value ($m), 2002-2011 97
Table 48: Pulmonary Arterial Hypertension Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011 98
Table 49: Pulmonary Arterial Hypertension Therapeutics Market, France, Patient Volume (absolute), 2002-2011 99
Table 50: Pulmonary Arterial Hypertension Therapeutics Market, France, Treatment Usage Patterns, 2002-2011 100
Table 51: Pulmonary Arterial Hypertension Therapeutics Market, France, Sales Value ($m), 2011-2020 104
Table 52: Pulmonary Arterial Hypertension Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 105
Table 53: Pulmonary Arterial Hypertension Therapeutics Market, France, Patient Volume (absolute), 2011-2020 106
Table 54: Pulmonary Arterial Hypertension Market, France, Treatment Usage Patterns, 2011-2020 107
Table 55: Pulmonary Arterial Hypertension Therapeutics Market, France, Drug Sales ($m), 2002-2011 109
Table 56: Pulmonary Arterial Hypertension Therapeutics Market, France, Drug Sales ($m), 2011-2020 110
Table 57: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Sales Value ($m), 2002-2011 112
Table 58: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011 113
Table 59: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Patient Volume (absolute), 2002-2011 114
Table 60: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Treatment Usage Patterns, 2002-2011 115
Table 61: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Sales Value ($m), 2011-2020 119
Table 62: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 120
Table 63: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Patient Volume (absolute), 2011-2020 121
Table 64: Pulmonary Arterial Hypertension Market, Italy, Treatment Usage Patterns, 2011-2020 122
Table 65: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Drug Sales ($m), 2002-2011 124
Table 66: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Drug Sales ($m), 2011-2020 125
Table 67: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Sales Value($m), 2002-2011 127
Table 68: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011 128
Table 69: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Patient Volume (absolute), 2002-2011 129
Table 70: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Treatment Usage Patterns, 2002-2011 130
Table 71: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Sales Value ($m), 2011-2020 133
Table 72: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 134
Table 73: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Patient Volume (absolute), 2011-2020 135
Table 74: Pulmonary Arterial Hypertension Market, Spain, Treatment Usage Patterns, 2011-2020 136
Table 75: Pulmonary Arterial Hypertension Market, Spain, Drug Sales ($m), 2002-2011 138
Table 76: Pulmonary Arterial Hypertension Market, Spain, Drug Sales ($m), 2011-2020 139
Table 77: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Sales Value($m), 2002-2011 141
Table 78: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011 142
Table 79: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Patient Volume (absolute), 2002-2011 143
Table 80: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2011 144
Table 81: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Sales Value ($m), 2011-2020 147
Table 82: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 148
Table 83: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Patient Volume (absolute), 2011-2020 149
Table 84: Pulmonary Arterial Hypertension Market, Japan, Treatment Usage Patterns, 2011-2020 150
Table 85: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 152
Table 86: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Drug Sales ($m), 2011-2020 153
Table 87: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Sales Value ($m), 2002-2011 154
Table 88: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011 155
Table 89: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Patient Volume, 2002-2011 156
Table 90: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Treatment Usage Patterns, 2002-2011 157
Table 91: Pulmonary Arterial Hypertension Market, Brazil, Sales Value ($m), 2011-2020 160
Table 92: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 161
Table 93: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Patient Volume, 2011-2020 162
Table 94: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020 163
Table 95: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Sales Value ($m), 2002-2011 165
Table 96: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011 166
Table 97: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Patient Volume (absolute), 2002-2011 167
Table 98: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Treatment Usage Patterns, 2002-2011 168
Table 99: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Sales Value ($m), 2011-2020 171
Table 100: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 172
Table 101: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Patient Volume (absolute), 2011-2020 173
Table 102: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020 174
Table 103: Pulmonary Arterial Hypertension Therapeutics Market, India, Sales Value ($m), 2002-2011 176
Table 104: Pulmonary Arterial Hypertension Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011 177
Table 105: Pulmonary Arterial Hypertension Therapeutics Market, India, Patient Volume (absolute), 2002-2011 178
Table 106: Pulmonary Arterial Hypertension Therapeutics Market, India, Treatment Usage Patterns, 2002-2011 179
Table 107: Pulmonary Arterial Hypertension Therapeutics Market, India, Sales Value ($m), 2011-2020 182
Table 108: Pulmonary Arterial Hypertension Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 183
Table 109: Pulmonary Arterial Hypertension Therapeutics Market, India, Patient Volume (absolute), 2011-2020 184
Table 110: Pulmonary Arterial Hypertension Therapeutics Market, India, Treatment Usage Patterns, 2011-2020 185
Table 111: Pulmonary Arterial Hypertension Therapeutics Market, China, Sales Value ($m), 2002-2011 187
Table 112: Pulmonary Arterial Hypertension Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011 188
Table 113: Pulmonary Arterial Hypertension Therapeutics Market, China, Patient Volume, 2002-2011 189
Table 114: Pulmonary Arterial Hypertension Therapeutics Market, China, Treatment Usage Patterns, 2002-2011 190
Table 115: Pulmonary Arterial Hypertension Market, China, Sales Value ($m), 2011-2020 193
Table 116: Pulmonary Arterial Hypertension Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 194
Table 117: Pulmonary Arterial Hypertension Therapeutics Market, China, Patient Volume, 2011-2020 195
Table 118: Pulmonary Arterial Hypertension Therapeutics Market, China, Treatment Usage Patterns, 2011-2020 196
Table 119: Effects of Tracleer on 6-minute walk distance 203
Table 120: Change from the Baseline in 6-Minute Walk Distance 205
Table 121: Major Marketed Products Comparison in the Pulmonary Arterial Hypertension Therapeutics Market, 2011 222
Table 122: Pulmonary Arterial Hypertension Pipeline, Pre-registration, 2011 227
Table 123: Pulmonary Arterial Hypertension Pipeline, Phase III, 2011 228
Table 124: Pulmonary Arterial Hypertension Pipeline, Phase II, 2011 228
Table 125: Pulmonary Arterial Hypertension Pipeline, Phase I, 2011 228
Table 126: Pulmonary Arterial Hypertension Pipeline, Pre-clinical, 2011 229
Table 127: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Status, 2011 236
Table 128: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Country, 2011 238
Table 129: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Phase, 2011 239
Table 130: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2011 240
Table 131: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials, Leading Sponsors, 2011 241
Table 132: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, 2011 242
Table 133: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, 2011 243
Table 134: Actelion - Respiratory Pipeline Portfolio 250
Table 135: United Therapeutics Corporation- Respiratory Pipeline Portfolio 256
Table 136: Novartis - Respiratory Pipeline Portfolio 262
Table 137: Bayer - Respiratory Pipeline Portfolio 267

List of Figures

1.2 List of Figures
Figure 1: Pulmonary Arterial Hypertension Pathophysiology 21
Figure 2: Pulmonary Hypertension, Diagnostic Algorithm 23
Figure 3: Pulmonary Arterial Hypertension, Treatment Algorithm, 2011 28
Figure 4: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m), 2002-2011 31
Figure 5: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2011 33
Figure 6: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011 35
Figure 7: Pulmonary Arterial Hypertension Market, Global, Patient Volume, 2002-2011 36
Figure 8: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, 2002-2011 37
Figure 9: Pulmonary Arterial Hypertension Therapeutics Market, Global, Market Drivers and Restraints, 2011 39
Figure 10: Pulmonary Arterial Hypertension Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011 40
Figure 11: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m), 2011-2020 41
Figure 12: Pulmonary Arterial Hypertension Therapeutics Market, Global, Sales Value ($m) by Country, 2011-2020 43
Figure 13: Pulmonary Arterial Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020 45
Figure 14: Pulmonary Arterial Hypertension Therapeutics Market, Global, Patient Volume, 2011-2020 46
Figure 15: Pulmonary Arterial Hypertension Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 47
Figure 16: Pulmonary Arterial Hypertension Therapeutics Market, Global, Future Market Drivers and Restraints, 2011-2020 48
Figure 17: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Drug Sales ($m), 2002-2020 49
Figure 18: Pulmonary Arterial Hypertension Therapeutics Market, the US, Sales Value ($m), 2002-2011 51
Figure 19: Pulmonary Arterial Hypertension Therapeutics Market, the US, Annual Cost of Therapy ($), 2002-2011 52
Figure 20: Pulmonary Arterial Hypertension Therapeutics Market, the US, Patient Volume (absolute), 2002-2011 53
Figure 21: Pulmonary Arterial Hypertension Therapeutics Market, the US, Treatment Usage Patterns, 2002-2011 54
Figure 22: Pulmonary Arterial Hypertension Therapeutics Market, the US, Market Drivers and Restraints, 2011 55
Figure 23: Pulmonary Arterial Hypertension Therapeutics Market, the US, The Impact of Historical Events on the Market, 2011 57
Figure 24: Pulmonary Arterial Hypertension Therapeutics Market, the US, Sales Value ($m), 2011-2020 58
Figure 25: Pulmonary Arterial Hypertension Therapeutics Market, the US, Annual Cost of Therapy ($), 2011-2020 59
Figure 26: Pulmonary Arterial Hypertension Therapeutics Market, the US, Patient Volume (absolute), 2011-2020 60
Figure 27: Pulmonary Arterial Hypertension Market, the US, Treatment Usage Patterns, 2011-2020 61
Figure 28: Pulmonary Arterial Hypertension Therapeutics Market, the US, Future Market Drivers and Restraints, 2011-2020 62
Figure 29: Pulmonary Arterial Hypertension Therapeutics Market, the US, Drug Sales ($m), 2002-2020 63
Figure 30: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Sales Value ($m), 2002-2011 66
Figure 31: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2011 67
Figure 32: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Patient Volume (absolute), 2002-2011 68
Figure 33: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Treatment Usage Patterns, 2002-2011 69
Figure 34: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Market Drivers and Restraints, 2011 70
Figure 35: Pulmonary Arterial Hypertension Therapeutics Market, the UK, the Impact of Historical Events on the Market, 2011 72
Figure 36: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Sales Value ($m), 2011-2020 73
Figure 37: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011-2020 74
Figure 38: Pulmonary Arterial Hypertension Market, the UK, Patient Volume (absolute), 2011-2020 75
Figure 39: Pulmonary Arterial Hypertension Market, the UK, Treatment Usage Patterns, 2011-2020 76
Figure 40: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Future Market Drivers and Restraints, 2011-2020 77
Figure 41: Pulmonary Arterial Hypertension Therapeutics Market, the UK, Drug Sales ($m), 2002-2020 78
Figure 42: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Sales Value ($m), 2002-2011 81
Figure 43: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011 82
Figure 44: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Patient Volume (absolute), 2002-2011 83
Figure 45: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Treatment Usage Patterns, 2002-2011 84
Figure 46: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Market Drivers and Restraints, 2011 85
Figure 47: Pulmonary Arterial Hypertension Therapeutics Market, Germany, the Impact of Historical Events on the Market, 2011 87
Figure 48: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Sales Value ($m), 2011-2020 88
Figure 49: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020 89
Figure 50: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Patient Volume (absolute), 2011-2020 90
Figure 51: Pulmonary Arterial Hypertension Market, Germany, Treatment Usage Patterns, 2011-2020 91
Figure 52: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011-2020 92
Figure 53: Pulmonary Arterial Hypertension Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 93
Figure 54: Pulmonary Arterial Hypertension Therapeutics Market, France, Sales Value ($m), 2002-2011 96
Figure 55: Pulmonary Arterial Hypertension Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011 97
Figure 56: Pulmonary Arterial Hypertension Therapeutics Market, France, Patient Volume (absolute), 2002-2011 98
Figure 57: Pulmonary Arterial Hypertension Therapeutics Market, France, Treatment Usage Patterns, 2002-2011 99
Figure 58: Pulmonary Arterial Hypertension Therapeutics Market, France, Market Drivers and Restraints, 2011 100
Figure 59: Pulmonary Arterial Hypertension Therapeutics Market, France, the Impact of Historical Events on the Market, 2011 102
Figure 60: Pulmonary Arterial Hypertension Therapeutics Market, France, Sales Value ($m), 2011-2020 103
Figure 61: Pulmonary Arterial Hypertension Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020 104
Figure 62: Pulmonary Arterial Hypertension Therapeutics Market, France, Patient Volume (absolute), 2011-2020 105
Figure 63: Pulmonary Arterial Hypertension Market, France, Treatment Usage Patterns, 2011-2020 106
Figure 64: Pulmonary Arterial Hypertension Therapeutics Market, France, Future Market Drivers and Restraints, 2011-2020 107
Figure 65: Pulmonary Arterial Hypertension Therapeutics Market, France, Drug Sales ($m), 2002-2020 108
Figure 66: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Sales Value ($m), 2002-2011 111
Figure 67: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011 112
Figure 68: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Patient Volume (absolute), 2002-2011 113
Figure 69: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Treatment Usage Patterns, 2002-2011 114
Figure 70: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Market Drivers and Restraints, 2011 115
Figure 71: Pulmonary Arterial Hypertension Therapeutics Market, Italy, the Impact of Historical Events on the Market, 2011 117
Figure 72: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Sales Value ($m), 2011-2020 118
Figure 73: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020 119
Figure 74: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Patient Volume (absolute), 2011-2020 120
Figure 75: Pulmonary Arterial Hypertension Market, Italy, Treatment Usage Patterns, 2011-2020 121
Figure 76: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011-2020 122
Figure 77: Pulmonary Arterial Hypertension Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 123
Figure 78: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Sales Value ($m), 2002-2011 126
Figure 79: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011 127
Figure 80: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Patient Volume (absolute), 2002-2011 128
Figure 81: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Treatment Usage Patterns, 2002-2011 129
Figure 82: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Market Drivers and Restraints, 2011 130
Figure 83: Pulmonary Arterial Hypertension Therapeutics Market, Spain, the Impact of Historical Events on the Market, 2011 131
Figure 84: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Sales Value ($m), 2011-2020 132
Figure 85: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020 133
Figure 86: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Patient Volume (absolute), 2011-2020 134
Figure 87: Pulmonary Arterial Hypertension Market, Spain, Treatment Usage Patterns, 2011-2020 135
Figure 88: Pulmonary Arterial Hypertension Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011-2020 136
Figure 89: Pulmonary Arterial Hypertension Market, Spain, Drug Sales ($m), 2002-2020 137
Figure 90: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Sales Value ($m), 2002-2011 140
Figure 91: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011 141
Figure 92: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Patient Volume (absolute), 2002-2011 142
Figure 93: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2011 143
Figure 94: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Market Drivers and Restraints, 2011 144
Figure 95: Pulmonary Arterial Hypertension Therapeutics Market, Japan, the Impact of Historical Events on the Market, 2011 145
Figure 96: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Sales Value ($m), 2011-2020 146
Figure 97: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020 147
Figure 98: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Patient Volume (absolute), 2011-2020 148
Figure 99: Pulmonary Arterial Hypertension Market, Japan, Treatment Usage Patterns, 2011-2020 149
Figure 100: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011-2020 150
Figure 101: Pulmonary Arterial Hypertension Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 151
Figure 102: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Sales Value ($m), 2002-2011 153
Figure 103: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011 154
Figure 104: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Patient Volume (absolute), 2002-2011 155
Figure 105: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Treatment Usage Patterns, 2002-2011 156
Figure 106: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 157
Figure 107: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 158
Figure 108: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Sales Value ($m), 2011-2020 159
Figure 109: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020 160
Figure 110: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Patient Volume (absolute), 2011-2020 161
Figure 111: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020 162
Figure 112: Pulmonary Arterial Hypertension Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011-2020 163
Figure 113: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Sales Value ($m), 2002-2011 164
Figure 114: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011 165
Figure 115: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Patient Volume (absolute), 2002-2011 166
Figure 116: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Treatment Usage Patterns, 2002-2011 167
Figure 117: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Market Drivers and Restraints, 2011 168
Figure 118: Pulmonary Arterial Hypertension Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2011 169
Figure 119: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Sales Value ($m), 2011-2020 170
Figure 120: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020 171
Figure 121: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Patient Volume (absolute), 2011-2020 172
Figure 122: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020 173
Figure 123: Pulmonary Arterial Hypertension Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011-2020 174
Figure 124: Pulmonary Arterial Hypertension Therapeutics Market, India, Sales Value ($m), 2002-2011 175
Figure 125: Pulmonary Arterial Hypertension Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011 176
Figure 126: Pulmonary Arterial Hypertension Therapeutics Market, India, Patient Volume (absolute), 2002-2011 177
Figure 127: Pulmonary Arterial Hypertension Therapeutics Market, India, Treatment Usage Patterns, 2002-2011 178
Figure 128: Pulmonary Arterial Hypertension Therapeutics Market, India, Market Drivers and Restraints, 2011 179
Figure 129: Pulmonary Arterial Hypertension Therapeutics Market, India, The Impact of Historical Events on the Market, 2011 180
Figure 130: Pulmonary Arterial Hypertension Therapeutics Market, India, Sales Value ($m), 2011-2020 181
Figure 131: Pulmonary Arterial Hypertension Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020 182
Figure 132: Pulmonary Arterial Hypertension Therapeutics Market, India, Patient Volume (absolute), 2011-2020 183
Figure 133: Pulmonary Arterial Hypertension Therapeutics Market, India, Treatment Usage Patterns, 2011-2020 184
Figure 134: Pulmonary Arterial Hypertension Therapeutics Market, India, Future Market Drivers and Restraints, 2011-2020 185
Figure 135: Pulmonary Arterial Hypertension Therapeutics Market, China, Sales Value ($m), 2002-2011 186
Figure 136: Pulmonary Arterial Hypertension Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011 187
Figure 137: Pulmonary Arterial Hypertension Therapeutics Market, China, Patient Volume (absolute), 2002-2011 188
Figure 138: Pulmonary Arterial Hypertension Therapeutics Market, China, Treatment Usage Patterns, 2002-2011 189
Figure 139: Pulmonary Arterial Hypertension Therapeutics Market, China, Market Drivers and Restraints, 2011 190
Figure 140: Pulmonary Arterial Hypertension Therapeutics Market, China, The Impact of Historical Events on the Market, 2011 191
Figure 141: Pulmonary Arterial Hypertension Therapeutics Market, China, Sales Value ($m), 2011-2020 192
Figure 142: Pulmonary Arterial Hypertension Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020 193
Figure 143: Pulmonary Arterial Hypertension Therapeutics Market, China, Patient Volume (absolute), 2011-2020 194
Figure 144: Pulmonary Arterial Hypertension Therapeutics Market, China, Treatment Usage Patterns, 2011-2020 195
Figure 145: Pulmonary Arterial Hypertension Therapeutics Market, China, Future Market Drivers and Restraints, 2011-2020 196
Figure 146: Opportunity and Unmet Need in the Pulmonary Arterial Hypertension Therapeutics Market, 2011 198
Figure 147: Strategic Competitor Assessment of the Major Marketed Products in Pulmonary Arterial Hypertension Therapeutics, 2011 200
Figure 148: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Tracleer, Sales Forecast ($m), 2002-2020 203
Figure 149: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Tracleer, Market Share Analysis (%), 2011 204
Figure 150: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Letairis/Volibris, Sales Forecast ($m), 2002-2020 206
Figure 151: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Letairis, Market Share Analysis (%), 2011 207
Figure 152: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Adcirca, Sales Forecast ($m), 2002-2020 209
Figure 153: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Adcirca, Market Share Analysis (%), 2011 210
Figure 154: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Revatio, Sales Forecast ($m), 2002-2020 212
Figure 155: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Revatio, Market Share Analysis (%), 2011 213
Figure 156: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Remodulin, Sales Forecast ($m), 2002-2020 215
Figure 157: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Remodulin, Market Share Analysis (%), 2011 216
Figure 158: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Tyvaso, Sales Forecast ($m), 2002-2020 217
Figure 159: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Ventavis, Sales Forecast ($m), 2002-2020 219
Figure 160: Pulmonary Arterial Hypertension Therapeutics Market, Major Markets, Ventavis, Market Share Analysis (%), 2011 220
Figure 161: Pulmonary Arterial Hypertension, Pipeline by Phase of Development, 2011 223
Figure 162: Pulmonary Arterial Hypertension, Global, Pipeline by Mechanism of Action, 2011 224
Figure 163: Pulmonary Arterial Hypertension, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011 225
Figure 164: Pulmonary Arterial Hypertension, Global, Technology Trends Description of Pipeline Drugs, 2011 225
Figure 165: Pulmonary Arterial Hypertension Pipeline by Phase of Clinical Development, 2011 226
Figure 166: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Status, 2011 236
Figure 167: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Country, 2011 237
Figure 168: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Phase, 2011 238
Figure 169: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2011 239
Figure 170: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials, Leading Sponsors, 2011 240
Figure 171: Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, 2011 241
Figure 172: Pulmonary Arterial Hypertension Market, Global, Clinical Trials, Average Number of Patients Recruited, 2011 242
Figure 173: Pulmonary Arterial Hypertension, Global, Key Events Impacting the Future Market, 2011 243
Figure 174: Implications for Future Market Competition in Pulmonary Arterial Hypertension Therapeutics Market, 2011 244
Figure 175: Pulmonary Arterial Hypertension Therapeutics Market: Pipeline by Company, 2011 245
Figure 176: Pulmonary Arterial Hypertension, Actelion, SWOT Analysis 2011 247
Figure 177: Pulmonary Arterial Hypertension, United Therapeutics Corporation, SWOT Analysis, 2011 251
Figure 178: Pulmonary Arterial Hypertension, Novartis AG, SWOT Analysis, 2011 256
Figure 179: Pulmonary Arterial Hypertension, Bayer, SWOT Analysis, 2011 263
Figure 180: Pulmonary Arterial Hypertension, Key Data Inputs from Key Opinion Leaders Interviews, 2011 269
Figure 181: GlobalData Market Forecasting Model 276